^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    Chr t(4;14)

    Apply
    Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma (NCT05208307)
    Phase 2
    Emory University
    Recruiting
    Last update posted :
    08/12/2024
    Initiation :
    07/21/2022
    Primary completion :
    10/21/2025
    Completion :
    10/21/2026
    CD4
    |
    Chr t(4;14) • Chr t(14;16)
    |
    pomalidomide • Blenrep (belantamab mafodotin-blmf) • Hemady (dexamethasone tablets)
    Haploidentical Stem Cell Transplant With Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL (NCT03524235)
    Phase 1
    Noah Merin
    Active, not recruiting
    Last update posted :
    06/04/2024
    Initiation :
    07/18/2018
    Primary completion :
    11/07/2021
    Completion :
    11/01/2031
    MYC • CD20 • HLA-DRB1 • CD4 • HLA-DQB1 • HLA-B
    |
    Chr del(17p) • Chr del(11q) • Chr t(4;14) • Chr t(14;16) • CD20 expression
    |
    Rituxan (rituximab) • bendamustine • fludarabine IV • Belrapzo (bendamustine RTD)
    ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma (NCT03441958)
    Phase 1/2
    Ciusss de L'Est de l'Île de Montréal
    Active, not recruiting
    Last update posted :
    02/08/2024
    Initiation :
    03/07/2018
    Primary completion :
    10/28/2023
    Completion :
    10/17/2025
    CD34
    |
    Chr del(17p) • Chr t(4;14) • Chr t(14;16) • Chr t(14;20) • C1As
    |
    cyclophosphamide • melphalan • dorocubicel (UM171 cell therapy)
    S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis (NCT03499808)
    Phase 2
    SWOG Cancer Research Network
    Active, not recruiting
    Last update posted :
    01/04/2024
    Initiation :
    06/06/2018
    Primary completion :
    12/31/2023
    Completion :
    07/31/2025
    NPPB
    |
    Chr t(11;14) • Chr t(4;14) • Chr t(14;16)
    |
    Sarclisa (isatuximab-irfc)
    A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma (KTX-MMSET-001) (NCT05651932)
    Phase 1
    K36 Therapeutics, Inc.
    Recruiting
    Last update posted :
    10/24/2023
    Initiation :
    02/22/2023
    Primary completion :
    12/01/2024
    Completion :
    10/01/2025
    NSD2
    |
    Chr t(4;14)
    |
    KTX-1001
    Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients (NCT02308280)
    Phase 2
    Maisonneuve-Rosemont Hospital
    Completed
    Last update posted :
    10/19/2023
    Initiation :
    11/01/2014
    Primary completion :
    09/27/2018
    Completion :
    09/27/2023
    HLA-B • HLA-C
    |
    Chr del(17p) • Chr t(4;14) • Chr t(14;16) • Chr t(14;20) • C1As
    |
    bortezomib • melphalan
    Immuno-PRISM (PRecision Intervention Smoldering Myeloma) (NCT05469893)
    Phase 2
    Irene Ghobrial, MD
    Recruiting
    Last update posted :
    08/01/2023
    Initiation :
    08/10/2022
    Primary completion :
    07/31/2030
    Completion :
    07/31/2030
    TP53
    |
    TP53 mutation • Chr t(4;14) • Chr t(14;16)
    |
    lenalidomide • dexamethasone • Tecvayli (teclistamab-cqyv)
    Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma (DETER-SMM) (NCT03937635)
    Phase 3
    ECOG-ACRIN Cancer Research Group
    Recruiting
    Last update posted :
    06/23/2023
    Initiation :
    09/16/2019
    Primary completion :
    12/31/2029
    Completion :
    12/31/2029
    CD34
    |
    Chr t(4;14)
    |
    lenalidomide • Darzalex (daratumumab) • dexamethasone
    CAR- PRISM (PRecision Intervention Smoldering Myeloma) (NCT05767359)
    Phase 2
    Dana-Farber Cancer Institute
    Recruiting
    Last update posted :
    06/19/2023
    Initiation :
    04/19/2023
    Primary completion :
    01/15/2026
    Completion :
    01/15/2040
    TP53
    |
    TP53 mutation • Chr t(4;14) • Chr t(14;16)
    |
    cyclophosphamide • fludarabine IV • Carvykti (ciltacabtagene autoleucel)
    Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma (NCT05422027)
    Phase 1/2
    Xia Zhongjun
    Recruiting
    Last update posted :
    02/27/2023
    Initiation :
    07/25/2022
    Primary completion :
    06/30/2025
    Completion :
    12/31/2025
    TP53
    |
    TP53 mutation • Chr t(4;14) • Chr t(14;16)
    |
    lenalidomide • bortezomib • Xpovio (selinexor)
    Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT02960646)
    Phase 1
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    02/16/2023
    Initiation :
    01/18/2017
    Primary completion :
    02/13/2023
    Completion :
    02/13/2023
    FLT3 • DNMT3A • ASXL1 • KMT2A • TET2 • PHF6
    |
    FLT3 mutation • DNMT3A mutation • Chr t(4;14) • Chr t(14;16) • MLL rearrangement
    |
    Rituxan (rituximab) • cyclophosphamide • melphalan • Truxima (rituximab-abbs) • fludarabine IV • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Neupogen (filgrastim) • Novex (rituximab biosimilar) • cyclophosphamide intravenous
    Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma (NCT05722405)
    Phase 4
    Second Affiliated Hospital, School of Medicine,...
    Recruiting
    Last update posted :
    02/10/2023
    Initiation :
    07/01/2022
    Primary completion :
    06/30/2024
    Completion :
    07/31/2025
    TP53
    |
    TP53 mutation • Chr t(4;14) • Chr t(14;16)
    |
    lenalidomide • Ninlaro (ixazomib)
    Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302) (NCT02440464)
    Phase 2
    National Heart, Lung, and Blood Institute (NHLBI)
    Completed
    Last update posted :
    01/04/2023
    Initiation :
    08/01/2015
    Primary completion :
    10/01/2020
    Completion :
    10/01/2020
    HLA-DRB1 • HLA-B • HLA-C
    |
    Chr t(4;14) • Chr t(14;16) • Chr t(14;20)
    |
    bortezomib • Ninlaro (ixazomib) • melphalan • fludarabine IV
    HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies (NCT01119066)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Completed
    Last update posted :
    08/05/2022
    Initiation :
    05/03/2010
    Primary completion :
    03/30/2021
    Completion :
    03/30/2021
    CD34
    |
    Chr t(4;14) • Chr t(14;16) • Chr t(15;17)
    |
    cyclophosphamide • clofarabine • melphalan • fludarabine IV • thiotepa • busulfan
    Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions (NCT01131169)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Completed
    Last update posted :
    12/02/2021
    Initiation :
    05/01/2010
    Primary completion :
    05/15/2020
    Completion :
    05/15/2020
    HLA-DRB1 • HLA-DQB1
    |
    Chr t(4;14) • Chr t(14;16)
    |
    melphalan • fludarabine IV • busulfan